Poorly differentiated thyroid carcinoma : An underdiagnosed entity.

Dettmer, Matthias S.; Schmitt, Anja; Komminoth, P; Perren, Aurel (2019). Poorly differentiated thyroid carcinoma : An underdiagnosed entity. (In Press). Der Pathologe Springer 10.1007/s00292-019-0600-9

[img]
Preview
Text
Dettmer2019_Article_PoorlyDifferentiatedThyroidCar.pdf - Published Version
Available under License Creative Commons: Attribution (CC-BY).

Download (1MB) | Preview

Poorly differentiated thyroid carcinomas (PDTCs) are a rare subtype of thyroid carcinomas that are biologically situated between well-differentiated papillary/follicular thyroid carcinomas and anaplastic thyroid carcinomas (ATCs).The diagnosis of conventional as well as oncocytic poorly differentiated thyroid carcinoma is difficult and often missed in daily routine. The current WHO criteria to allow the diagnosis of PDTCs are based on the results of a consensus meeting held in Turin in 2006. Even a minor poorly differentiated component of only 10%of a given carcinoma significantly affects patient prognosis and the oncocytic subtype may even have a worse outcome. Immunohistochemistry is not much help and is mostly used to exclude a medullary thyroid carcinoma with calcitonin and to establish a follicular cell of origin via thyroglobulin staining.Due to the concept of stepwise dedifferentiation, there is a vast overlap of different molecular alterations like BRAF, RAS, CTNNB1, TP53 and others between different thyroid carcinoma subtypes. A distinctive molecular tumor profile is therefore currently not available.PDTCs have a unique miRNA signature, which separates them from other thyroid carcinomas. The average relapse free survival is less than one year and about 50% of patients die of the disease. Modern tyrosine kinase inhibitors offer in conjunction with powerful molecular diagnostic new chances in these difficult to treat carcinomas.

Item Type:

Journal Article (Review Article)

Division/Institute:

04 Faculty of Medicine > Service Sector > Institute of Pathology

UniBE Contributor:

Dettmer, Matthias; Schmitt Kurrer, Anja and Perren, Aurel

Subjects:

500 Science > 570 Life sciences; biology
600 Technology > 610 Medicine & health

ISSN:

1432-1963

Publisher:

Springer

Language:

English

Submitter:

Matthias Dettmer

Date Deposited:

25 Sep 2019 10:29

Last Modified:

24 Oct 2019 05:29

Publisher DOI:

10.1007/s00292-019-0600-9

PubMed ID:

31273418

Uncontrolled Keywords:

MicroRNA Poorly differentiated thyroid carcinoma Prognosis Thyroid neoplasm Tyrosine kinase inhibitor

BORIS DOI:

10.7892/boris.133291

URI:

https://boris.unibe.ch/id/eprint/133291

Actions (login required)

Edit item Edit item
Provide Feedback